Lilly’s Verzenio plus fulvestrant improves overall survival in MONARCH 2

This article was originally published here

The late-stage study called MONARCH 2 met its secondary endpoint of overall survival for Verzenio in combination with the endocrine therapy fulvestrant. The trial involved 669 patients, who

The post Lilly’s Verzenio plus fulvestrant improves overall survival in MONARCH 2 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply